FSD Pharma Inc.
520 William Street
Cobourg, ON K9A 3A5 Canada
Phone: (647) 864-7969
FSD Pharma Inc. (“FSD” or “the Company”) is a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The Company is addressing certain diseases of the central nervous system as well as autoimmune disorders of the skin, gastrointestinal (GI) tract, and musculoskeletal system. Following FSD’s 2Q19 acquisition of Prismic Pharmaceuticals (“Prismic”)—forming part of the Company’s BioSciences subsidiary—FSD is also seeking to tackle the opioid crisis by developing non-addictive prescription drugs to treat pain and inflammation using a ultramicronized formulation of palmitolylethonalamide (PEA) or ultramicronized PEA. PEA interacts with endocannabinoid receptors throughout the body and is a naturally occurring anti-inflammatory. It’s anti-inflammatory and analgesic effects may help overcome the problem created by prolonged opioid use as it reduces the development of opioid tolerance and potentiates drug efficacy, thus allowing for the use of lower doses of opioids. FSD’s other subsidiary, FV Pharma, is a Licensed Producer under Canada’s Cannabis Act and Regulations, having received its Cultivation License on October 13, 2017 and its full Sale for Medical Purposes License on June 21, 2019. The Company is licensed to cultivate cannabis at its Cobourg, Ontario facility, reporting approximately C$260,000 in medical cannabis sales during 4Q19.
* The Corporate Snapshot was last updated on March 11, 2020.